Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC18A3 | Q16572 | 3/20 | 0.68 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.49 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.44 |
| ▸ | LTA4H | P09960 | 3/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | EBP | Q15125 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18386875 | 0.90 | SLC18A3 (0.71) | SLC18A3KCNA5LTA4HEBPKDM4E | |
| SCHEMBL10573537 | 0.90 | SLC18A3 (0.71) | SLC18A3KCNA5LTA4HEBPKDM4E | |
| SCHEMBL15610808 | 0.87 | SLC18A3 (0.66) | SLC18A3KCNA5LTA4HEBPKMT2A | |
| SCHEMBL14873965 | 0.87 | SLC18A3 (0.66) | SLC18A3KCNA5LTA4HEBPKMT2A | |
| SCHEMBL15610809 | 0.87 | SLC18A3 (0.66) | SLC18A3KCNA5LTA4HEBPKMT2A | |
| SCHEMBL12685154 | 0.87 | SLC18A3 (0.66) | SLC18A3KCNA5LTA4HEBPKMT2A | |
| SCHEMBL26879524 | 0.85 | SLC18A3 (0.50) | SLC18A3GRIN2BLTA4HL3MBTL1KDM4E | |
| SCHEMBL10511383 | 0.84 | SLC18A3 (0.62) | SLC18A3KCNA5LTA4HKDM4EALDH1A1 | |
| SCHEMBL25417757 | 0.81 | SLC18A3 (0.62) | SLC18A3KCNA5LTA4HEBPALDH1A1 | |
| SCHEMBL6391371 | 0.81 | SLC18A3 (1.00) | SLC18A3KCNA5LTA4HL3MBTL1EBP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200115354-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2020-04-16 | — | — | US | disclosed |
| US-10457654-B2 | Therapeutic compounds and methods of use thereof | GENENTECH, INC. (US) | 2019-10-29 | — | — | US | disclosed |
| WO-2018072602-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2018-04-26 | — | — | WO | disclosed |
| US-20180105504-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2018-04-19 | — | — | US | disclosed |
| US-20180105504-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2018-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200115354-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | NPY5R, REN, F12 | SLC18A3 2528/4885KCNA5 146/4885GRIN2B 1312/4885 |
| US-10457654-B2 | Therapeutic compounds and methods of use thereof | NPY5R, REN, F12 | SLC18A3 2528/4885KCNA5 146/4885GRIN2B 1312/4885 |
| US-20180105504-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | NPY5R, REN, F12 | SLC18A3 2402/4885KCNA5 160/4885GRIN2B 1237/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.